首页> 外国专利> HSP70 BINDING COMPOUND, USE, ANTITUMOUR PHARMACEUTICAL COMPOSITION, GENE CONSTRUCT FOR EXPRESSING AN HSP70 BINDER, PRODUCTION PROCESS, PROCESS FOR EVALUATING TUMOUR CELLS, METHOD OF SENSITIZATION OF TUMOUR CELLS TO CHEMOTHERAPEUTIC DRUGS

HSP70 BINDING COMPOUND, USE, ANTITUMOUR PHARMACEUTICAL COMPOSITION, GENE CONSTRUCT FOR EXPRESSING AN HSP70 BINDER, PRODUCTION PROCESS, PROCESS FOR EVALUATING TUMOUR CELLS, METHOD OF SENSITIZATION OF TUMOUR CELLS TO CHEMOTHERAPEUTIC DRUGS

机译:HSP70结合剂,用途,抗药性成分,表达HSP70结合剂的基因结构,生产过程,评估肿瘤细胞的过程,将肿瘤细胞敏化为化疗药物的方法

摘要

The present invention provides the use of the HspBP1 protein or portion thereof in preparing an antitumour pharmaceutical composition, the combination thereof with one or more chemotherapeutic agents being optional. The following are also disclosed: a gene construct for expressing said binder, a production process, a process for evaluating tumour cells, and a method of sensitization of tumours to chemotherapeutic drugs. The invention also provides a novel in vivo and in vitro experimental model for developing/evaluating antitumour agents. The pharmaceutical compositions of the invention provide antitumour activity and are highly specific for neoplastic cells, resulting in less cytotoxicity for cells with normal cell division. These and other advantages of the invention characterize a solution for the inconveniences of the currently known chemotherapeutic treatments.
机译:本发明提供了HspBP1蛋白或其部分在制备抗肿瘤药物组合物中的用途,其与一种或多种化学治疗剂的组合是任选的。还公开了以下内容:用于表达所述结合剂的基因构建体,生产方法,评估肿瘤细胞的方法以及使肿瘤对化学治疗药物敏感的方法。本发明还提供了用于开发/评估抗肿瘤剂的新颖的体内体外实验模型。本发明的药物组合物提供抗肿瘤活性并且对肿瘤细胞具有高度特异性,从而导致具有正常细胞分裂的细胞的细胞毒性较小。本发明的这些和其他优点是解决目前已知的化学治疗方法的不便的解决方案。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号